197 related articles for article (PubMed ID: 19642026)
1. Selective immune adsorption treatment of severe Guillain Barré syndrome in the intensive care unit.
Galldiks N; Dohmen C; Neveling M; Fink GR; Haupt WF
Neurocrit Care; 2009 Dec; 11(3):317-21. PubMed ID: 19642026
[TBL] [Abstract][Full Text] [Related]
2. Plasma exchange after initial intravenous immunoglobulin treatment in Guillain-Barré syndrome: critical reassessment of effectiveness and cost-efficiency.
Oczko-Walker M; Manousakis G; Wang S; Malter JS; Waclawik AJ
J Clin Neuromuscul Dis; 2010 Dec; 12(2):55-61. PubMed ID: 21386771
[TBL] [Abstract][Full Text] [Related]
3. Second IVIg course in Guillain-Barré syndrome patients with poor prognosis (SID-GBS trial): Protocol for a double-blind randomized, placebo-controlled clinical trial.
Walgaard C; Jacobs BC; Lingsma HF; Steyerberg EW; Cornblath DR; van Doorn PA;
J Peripher Nerv Syst; 2018 Dec; 23(4):210-215. PubMed ID: 30151941
[TBL] [Abstract][Full Text] [Related]
4. The Efficacy of Intravenous Immunoglobulin in Guillain-Barré Syndrome: The Experience of a Tertiary Medical Center.
Shalem D; Shemer A; Shovman O; Shoenfeld Y; Kivity S
Isr Med Assoc J; 2018 Dec; 20(12):754-760. PubMed ID: 30550005
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy for Guillain-Barré syndrome in the US hospitals.
Alshekhlee A; Hussain Z; Sultan B; Katirji B
J Clin Neuromuscul Dis; 2008 Sep; 10(1):4-10. PubMed ID: 18772694
[TBL] [Abstract][Full Text] [Related]
6. The role of immunotherapy in Guillain-Barré syndrome: understanding the mechanism of action.
Shahrizaila N; Yuki N
Expert Opin Pharmacother; 2011 Jul; 12(10):1551-60. PubMed ID: 21473704
[TBL] [Abstract][Full Text] [Related]
7. IVIG treatment and prognosis in Guillain-Barré syndrome.
van Doorn PA; Kuitwaard K; Walgaard C; van Koningsveld R; Ruts L; Jacobs BC
J Clin Immunol; 2010 May; 30 Suppl 1(Suppl 1):S74-8. PubMed ID: 20396937
[TBL] [Abstract][Full Text] [Related]
8. Intravenous immunoglobulin for Guillain-Barré syndrome.
Hughes RA; Swan AV; van Doorn PA
Cochrane Database Syst Rev; 2012 Jul; (7):CD002063. PubMed ID: 22786476
[TBL] [Abstract][Full Text] [Related]
9. Apheresis and selective adsorption plus immunoglobulin treatment in Guillain-Barré syndrome.
Haupt WF; Birkmann C; van der Ven C; Pawlik G
Ther Apher; 2000 Jun; 4(3):198-200. PubMed ID: 10910019
[TBL] [Abstract][Full Text] [Related]
10. Patient characteristics and the effects of intravenous immunoglobulin in patients with Guillain-Barre syndrome.
Guzey Aras Y; Tanik O; Dogan Güngen B; Kotan D
Ideggyogy Sz; 2016 Nov; 69(11-12):389-395. PubMed ID: 29733556
[TBL] [Abstract][Full Text] [Related]
11. Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology.
Hughes RA; Wijdicks EF; Barohn R; Benson E; Cornblath DR; Hahn AF; Meythaler JM; Miller RG; Sladky JT; Stevens JC;
Neurology; 2003 Sep; 61(6):736-40. PubMed ID: 14504313
[TBL] [Abstract][Full Text] [Related]
12. Intravenous immunoglobulin therapy for Guillain-Barré syndrome with IgG anti-GM1 antibody.
Kuwabara S; Mori M; Ogawara K; Hattori T; Oda S; Koga M; Yuki N
Muscle Nerve; 2001 Jan; 24(1):54-8. PubMed ID: 11150966
[TBL] [Abstract][Full Text] [Related]
13. Intravenous immunoglobulin in very severe childhood Guillain-Barré syndrome.
Singhi SC; Jayshree M; Singhi P; Banerjee S; Prabhakar S
Ann Trop Paediatr; 1999 Jun; 19(2):167-74. PubMed ID: 10690257
[TBL] [Abstract][Full Text] [Related]
14. Changes of Serum IgG Dimer Levels after Treatment with IVIg in Guillain-Barré Syndrome.
Svačina MKR; Röth P; Bobylev I; Sprenger A; Zhang G; Sheikh KA; Lehmann HC
J Neuroimmune Pharmacol; 2019 Dec; 14(4):642-648. PubMed ID: 31515689
[TBL] [Abstract][Full Text] [Related]
15. Management of Guillain-Barré syndrome with plasmapheresis or immunoglobulin: our experience from a tertiary care institute in South India.
Kishore CK; Vijayabhaskar J; Vishnu Vardhan R; Sainaresh VV; Sriramnaveen P; Sridhar AV; Varalaxmi B; Sandeep P; Ram R; Vengamma B; Siva Kumar V
Ren Fail; 2014 Jun; 36(5):732-6. PubMed ID: 24593239
[TBL] [Abstract][Full Text] [Related]
16. The usefulness of chief complaints to predict severity, ventilator dependence, treatment option, and short-term outcome of patients with Guillain-Barré syndrome: a retrospective study.
Wang Y; Shang P; Xin M; Bai J; Zhou C; Zhang HL
BMC Neurol; 2017 Nov; 17(1):200. PubMed ID: 29157205
[TBL] [Abstract][Full Text] [Related]
17. Association of Albumin Levels With Outcome in Intravenous Immunoglobulin-Treated Guillain-Barré Syndrome.
Fokkink WR; Walgaard C; Kuitwaard K; Tio-Gillen AP; van Doorn PA; Jacobs BC
JAMA Neurol; 2017 Feb; 74(2):189-196. PubMed ID: 28027337
[TBL] [Abstract][Full Text] [Related]
18. Recent advances of therapeutic apheresis in Guillain-Barré syndrome.
Haupt WF
Ther Apher; 2000 Aug; 4(4):271-4. PubMed ID: 10975472
[TBL] [Abstract][Full Text] [Related]
19. Intravenous immunoglobulin reduces serum tumor necrosis factor alpha in patients with Guillain-Barre syndrome.
Reuben S; Sumi MG; Mathai A; Nair MD; Radhakrishnan VV
Neurol India; 2003 Dec; 51(4):487-9. PubMed ID: 14742928
[TBL] [Abstract][Full Text] [Related]
20. High-dose immunoglobulin therapy for Guillain-Barré syndrome in Japanese children.
Yata J; Nihei K; Ohya T; Hirano Y; Momoi M; Maekawa K; Sakakihara Y;
Pediatr Int; 2003 Oct; 45(5):543-9. PubMed ID: 14521529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
